Product Images Gabapentin

This text describes several symptoms related to a medical condition. These symptoms include lack of coordination, viral infection, difficulty with speaking, tremor, swelling (usually of legs and feet), feeling tired, fever, feeling drowsy, nausea and vomiting, jerky movements, difficulty with coordination, double vision, and unusual eye movement. It is important to consult a healthcare professional for a proper diagnosis and treatment.*

TABLE 1. Gabapentin Dosage Based on Renal Function This table provides information on the recommended dosage of Gabapentin based on a patient's renal function. The dosage is determined based on the patient's creatinine clearance, which is a measure of kidney function. For patients with a creatinine clearance equal to or greater than 60 mL/min, the total daily dose ranges from 900 to 3600 mg. The recommended dose regimen is to take 300 mg three times a day (TID), 400 mg TID, 600 mg TID, 800 mg TID, or 1200 mg TID. For patients with a creatinine clearance between 30 and 59 mL/min, the total daily dose ranges from 400 to 1400 mg. The recommended dose regimen is to take 200 mg twice a day (BID), 300 mg BID, 400 mg BID, 500 mg BID, or 700 mg BID. For patients with a creatinine clearance between 15 and 29 mL/min, the total daily dose ranges from 200 to 700 mg. The recommended dose regimen is to take 200 mg once a day (QD), 300 mg QD, 400 mg QD, 500 mg QD, or 700 mg QD. For patients with a creatinine clearance of 15 mL/min or less, the recommended daily dose should be reduced in proportion to their creatinine clearance. Patients on hemodialysis should receive maintenance doses based on estimates of creatinine clearance, as indicated in the upper portion of the table. Additionally, a supplemental post-hemodialysis dose should be administered after each 4 hours of hemodialysis, as indicated in the lower portion of the table. The post-hemodialysis doses range from 1250 to 3500 mg. The table also provides explanations of the abbreviations used: TID means three times a day, BID means two times a day, and QD means a single daily dose.*

This text appears to be a table showing the risk and relative risk of events for different indications of antiepileptic drugs. The indications mentioned include epilepsy, psychiatric conditions, and other uses. The table provides data on the number of events per 1,000 patients for both placebo and drug patients. It also calculates the relative risk and risk difference between drug and placebo patients for each indication.*

This text provides a table detailing the adverse reactions observed in pooled placebo-controlled trials for the treatment of postherpetic neuralgia using Gabapentin. The table includes the percentage of patients experiencing various side effects for both the Gabapentin and placebo group. Some of the reported adverse reactions include asthenia, infection, accidental injury, diarrhea, dry mouth, constipation, nausea, vomiting, peripheral edema, weight gain, hyperglycemia, dizziness, somnolence, ataxia, abnormal thinking, abnormal gait, incoordination, pharyngitis, amblyopia, conjunctivitis, diplopia, and otitis media. Blurred vision is also mentioned in the text.*

This is a summary of adverse reactions observed in pooled placebo-controlled add-on trials in epilepsy patients aged 12 years and older who were treated with Gabapentin® compared to placebo. The table provides percentages of patients experiencing various adverse reactions in different body systems. Some of the common adverse reactions include fatigue, weight gain, back pain, peripheral edema, dyspepsia, dry mouth or throat, constipation, somnolence, dizziness, ataxia, nystagmus, tremor, dysarthria, amnesia, depression, abnormal thinking, abnormal coordination, pharyngitis, coughing, abrasion, impotence, diplopia, and amblyopia. Amblyopia is described as blurred vision. It is important to note that these adverse reactions occurred in the context of background antiepileptic drug therapy.*

This text provides information on controlled studies involving patients taking gabapentin for postherpetic neuralgia (PHN). The table lists the duration, dosages, and number of patients for two studies. Study 1 lasted 8 weeks and involved patients taking a target dose of 3600 mg/day of gabapentin, with 113 patients receiving gabapentin and 116 receiving a placebo. Study 2 lasted 7 weeks and involved patients taking dosages of 1800 mg/day and 2400 mg/day of gabapentin, with 223 patients receiving gabapentin and 111 receiving a placebo. In total, there were 336 patients receiving gabapentin and 221 receiving a placebo across the two studies. The last line indicates that the gabapentin was given in three divided doses per day (TID).*

This text appears to be a formula related to medical calculations. It seems to involve variables such as age, weight, and serum creatinine. However, without further context or clear formatting, it is difficult to provide a precise description or interpretation of the formula's purpose.*

Not available.*